As a super provider of diverse antibodies, Creative Biolabs offers customers several approaches for scFv generation such as one-stop solution for developing CAR from Hybridoma, which is a very mature and useful technology for scFv construction.
As we known, a variable region (Fv) always consists of a heavy chain variable region (VH) and a light chain variable region (VL), while a single-chain variable fragment (scFv) normally consists of a VH and a VL connected together via a peptide linker. Our seasoned scientists can generate a scFv from Hybridoma Cell Lines following this procedure: firstly, we immunize mice with the antigen, and then remove the spleen to get splenocytes (B cells). After the splenocytes and myeloma cells fusion step, hydridoma cell lines will be established for producing specific monoclonal antibodies. Our skilled scientists from Creative Biolabs can convert the Fv from full monoclonal antibody into a scFv, which can target the tumor antigen our customer interested in. Finally, we will clone this scFv, together with other CAR components into a Lentivirus vector for the future steps.
Creative Biolabs is a world leading expert in antibody engineering field, which can provide our clients with the best-class service in order to meet their research needs. Our years of experience guarantee we can offer you our high quality scFv generation.
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE